Introduction
============

Bladder cancer is one of the most common cancer types of the urological tract, with increasing incidence in recent years ([@b1-etm-0-0-7960]--[@b3-etm-0-0-7960]). Despite systemic therapy for bladder cancer, the clinical outcome is modest, mainly due to metastasis, recurrence and drug resistance ([@b4-etm-0-0-7960]). During the development and progression of bladder cancer, numerous tumour suppressors and oncogenes, including certain microRNAs (miRNAs/miRs) and long non-coding RNAs (lncRNAs), have been determined to be deregulated ([@b1-etm-0-0-7960],[@b5-etm-0-0-7960],[@b6-etm-0-0-7960]). Gaining insight into the molecular mechanisms of bladder cancer is beneficial for developing novel biomarkers and therapeutic targets for its diagnosis and treatment ([@b7-etm-0-0-7960]).

lncRNAs are a class of non-protein-coding transcripts with lengths of \>200 base pairs and are involved in the pathological process of numerous human diseases through regulating processes including cell proliferation, apoptosis, migration and angiogenesis ([@b8-etm-0-0-7960]--[@b12-etm-0-0-7960]). Accumulating evidence has indicated that numerous lncRNAs have either oncogenic or tumour-suppressive roles in bladder cancer ([@b13-etm-0-0-7960],[@b14-etm-0-0-7960]). For instance, the lncRNA activated by transforming growth factor-β (TGF-β) is upregulated in bladder cancer and promotes the proliferation, migration and invasion of bladder cancer cells by inhibiting the expression of miR-126 ([@b15-etm-0-0-7960]). Wang *et al* ([@b16-etm-0-0-7960]) determined a negative correlation between growth arrest specific 5 (GAS5) levels and clinical stage in bladder cancer, and overexpression of GAS5 reduced bladder cancer cell viability and induced apoptosis.

X inactivation is an early developmental process in mammalian females that transcriptionally silences one of the pairs of X chromosomes ([@b17-etm-0-0-7960]). The lncRNA X inactive specific transcript (XIST) is required for X inactivation during development ([@b18-etm-0-0-7960]). Recently, XIST has been reported to be frequently upregulated in various human cancer types and to function as an oncogene ([@b19-etm-0-0-7960],[@b20-etm-0-0-7960]). For instance, it may accelerate cervical cancer progression via upregulating Fus through competitively binding with miR-200a ([@b20-etm-0-0-7960]). In addition, XIST may promote gastric cancer progression through TGF-β1 via targeting miR-185 ([@b19-etm-0-0-7960]).

The oncogenic role of XIST in bladder cancer has also been reported ([@b21-etm-0-0-7960],[@b22-etm-0-0-7960]). For instance, Xu *et al* ([@b21-etm-0-0-7960]) suggested that the lncRNA XIST inhibits the stemness properties and tumourigenicity of bladder cancer cells through inhibiting the expression of miR-200c. In addition, XIST promotes cell growth and metastasis through regulating the miR-139-5p-mediated Wnt/β-catenin signalling pathway in bladder cancer ([@b22-etm-0-0-7960]). Recently, Wei *et al* ([@b23-etm-0-0-7960]) reported that XIST promoted pancreatic cancer cell proliferation through regulating the expression of miR-133a and epidermal growth factor receptor (EGFR). However, whether miR-133a is also involved in XIST-mediated bladder cancer has remained elusive.

In the present study, the clinical significance of XIST in bladder cancer was assessed and in addition, the regulatory mechanism of XIST in bladder cancer cell proliferation and migration were explored.

Materials and methods
=====================

### Clinical tissue samples

Bladder cancer tissues and adjacent tissues were collected from 52 primary bladder cancer patients at the Second Xiangya Hospital (Changsha, China) between March 2011 and April 2013. The clinical characteristics of the patients are summarized in [Table I](#tI-etm-0-0-7960){ref-type="table"} and included 32 male and 20 female patients, aged between 42--75 years. Prior to surgery, none of the cancer patients had been treated by chemotherapy or radiotherapy. The tissues were rapidly frozen in liquid nitrogen and stored until use.

### Cell culture and transfection

The SV-HUC-1 normal urinary tract epithelial cell line and four common bladder cancer cell lines, T24, 253J, RT112 and HT-1376, were obtained from the Cell Bank of the Chinese Academy of Sciences. These cell lines were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Thermo Fisher Scientific, Inc.) supplemented with 10% foetal bovine serum (Thermo Fisher Scientific, Inc.) at 37°C with 5% CO~2~. For cell transfection, 253J and RT112 cells were transfected with 100 nM XIST small interfering (si)RNA1 (5′-GCAAAUGAAAGCUACCAAU-3′; Thermo Fisher Scientific, Inc.), XIST siRNA2 (5′-GCACAAUAUCUUUGAACUA-3′; Thermo Fisher Scientific, Inc.) or 100 nM negative control (NC) siRNA (cat. no. 4459405; Thermo Fisher Scientific, Inc.) or co-transfected with 100 nM NC siRNA and 100 nM NC inhibitor (cat. no. 4464076; Thermo Fisher Scientific, Inc.), or 100 nM NC siRNA and 100 nM miR-133a inhibitor (cat. no. 4464084; Thermo Fisher Scientific, Inc.), or 100 nM XIST siRNA and 100 nM miR-133a inhibitor, or 100 nM XIST siRNA and 100 nM NC inhibitor using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocols. At 48 h after transfection, the cells were harvested and used for the subsequent assays.

### Reverse transcription-quantitative (RT-q)PCR

Total RNA was isolated from tissues and cell lines using TRIzol reagent (Thermo Fisher Scientific, Inc.) and RT was performed by processing 500 ng RNA with the First-Stand cDNA Synthesis Kit (Tiangen Biotech Co., Ltd) according to the manufacturer\'s protocols. qPCR analysis was performed using SYBR Green PCR Master Mix (Takara Bio, Inc.) according to the manufacturer\'s protocols. The reaction conditions were 95°C for 3 min followed by 40 cycles of 95°C for 15 sec and 60°C for 15 sec. Relative gene expression was calculated using the 2^−ΔΔCq^ method ([@b24-etm-0-0-7960]). GAPDH and U6 were used as internal references. The primers utilized in PCR were as follows: XIST forward, 5′-ACGCTGCATGTGTCCTTAG-3′ and reverse, 5′-GAGCCTCTTATAGCTGTTTG-3′; GAPDH forward, 5′-CTGGGCTACACTGAGCACC-3′ and reverse, 5′-AAGTGGTCGTTGAGGGCAATG-3′; miR-133a forward, 5′-TTTGGTCCCCTTCAACCAGCTG-3′ and reverse, 5′-TAAACCAAGGTAAAATGGTCGA-3′; U6 forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′.

### Cell Counting Kit-8 (CCK-8) assay

At 48 h after transfection, 253J and RT112 cells were seeded onto 96-well plates at 5,000 cells per well. After incubation at 37°C with 5% CO~2~ for 0, 24, 48 and 72 h, cell proliferation was measured using the CCK-8 assay (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocols. Absorbance was detected at an optical density of 450 nm by a spectrophotometer (BioRad Laboratories, Inc.).

### Wound healing assay

To study cell migration, transfected 253J and RT112 cells were seeded into 6-well plates. After culturing at 37°C with 5% CO~2~ for 24 h, a line was scraped into the monolayer with a 200-µl micropipette tip. The cells were washed twice with PBS and cultured in serum-free DMEM for 24 h. Images of the wounded area at 0 and 24 h were captured under a light microscope (CX22; Olympus Corporation).

### Bioinformatics analysis and luciferase reporter gene assay

The potential targeting miRs of the lncRNA XIST were predicted using RNAhybrid 2.12 (<http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/>) ([@b25-etm-0-0-7960]). XIST sequences containing the wild-type (WT) or mutant-type (MT) miR-133a binding sites were subcloned into the pmiR-GLo luciferase reporter vector (Promega Corp.). Lipofectamine 2000 was then used to transfect 253J and RT112 cells with miR-NC or miR-133a mimics together with the WT- or MT-XIST reporter plasmid according to the manufacturer\'s protocols. At 48 h after transfection, a Dual Luciferase Reporter Assay System (Promega Corp.) was used to determine luciferase activities according to the manufacturer\'s protocols.

### Statistical analysis

Values are expressed as the mean ± standard deviation. SPSS 20.0 software (IBM Corp.) was used for statistical analysis. An unpaired two-tailed Student\'s t-test was used to compare the differences between two groups. One-way analysis of variance followed by Tukey\'s post-hoc test was used for multiple comparisons. The association between XIST expression and the clinical features of bladder cancer patients was analysed using the chi-square test. For survival analysis, Kaplan-Meier survival curves were drawn and the log-rank test was applied. The Spearman rank correlation was used to analyse the correlation between the expression of XIST and miR-133a in bladder cancer tissues. P\<0.05 was considered to indicate statistical significance.

Results
=======

### Upregulation of XIST is associated with tumour progression and poor prognosis in bladder cancer

To explore the function of XIST in bladder cancer, its expression in the normal urinary tract epithelial cell line SV-HUC-1 and four common bladder cancer cell lines, T24, 253J, RT112 and HT-1376, was first examined. The results of the RT-qPCR analysis suggested that the expression levels of XIST were significantly increased in bladder cancer cells compared with those in SV-HUC-1 cells ([Fig. 1A](#f1-etm-0-0-7960){ref-type="fig"}). To confirm these results, 52 paired bladder cancer tissues and adjacent normal tissues were collected and assessed for expression of XIST. The results revealed that XIST was also significantly upregulated in bladder cancer tissues vs. adjacent normal tissues ([Fig. 1B](#f1-etm-0-0-7960){ref-type="fig"}). Furthermore, high XIST expression was significantly associated with the presence of metastasis, advanced tumour-nodes-metastasis (TNM) stage and a shorter survival time of bladder cancer patients ([Table I](#tI-etm-0-0-7960){ref-type="table"}, [Fig. 1C](#f1-etm-0-0-7960){ref-type="fig"}). It was therefore indicated that upregulation of XIST is associated with tumour progression and poor prognosis in bladder cancer.

### Inhibition of XIST suppresses bladder cancer cell proliferation and migration

In the present study, 253J and RT112 cells were subjected to *in vitro* loss-of-function experiments to further reveal the function of XIST in bladder cancer. 253J and RT112 cells were transfected with NC siRNA, or XIST siRNA1 or siRNA2. After transfection, the expression levels of XIST were significantly reduced in the XIST siRNA1 and siRNA2 groups compared with those in the siNC group ([Fig. 2A](#f2-etm-0-0-7960){ref-type="fig"}). As XIST siRNA1 exhibited a better suppressive effect on XIST expression, it was used in the subsequent experiments. The results of the CCK-8 assay indicated that silencing of XIST expression caused a reduction in bladder cancer cell proliferation ([Fig. 2B and C](#f2-etm-0-0-7960){ref-type="fig"}). Furthermore, as indicated in [Fig. 2D and E](#f2-etm-0-0-7960){ref-type="fig"}, the migration of 253J and RT112 cells was also inhibited after knockdown of XIST. Taken together, these results suggest that the inhibition of XIST suppresses bladder cancer growth and metastasis.

### XIST directly targets miR-133a in bladder cancer cells

Next, a Bioinformatics analysis was performed to predict potential XIST-miR interactions. The results indicated that miR-133a had a potential binding site in XIST ([Fig. 3A](#f3-etm-0-0-7960){ref-type="fig"}). Furthermore, knockdown of XIST expression significantly promoted miR-133a expression in bladder cancer cells ([Fig. 3B](#f3-etm-0-0-7960){ref-type="fig"}). To verify the predicted direct binding interaction, a luciferase reporter gene assay was then performed. As indicated in [Fig. 3C and D](#f3-etm-0-0-7960){ref-type="fig"}, miR-133a mimics significantly inhibited the luciferase activity of the XIST-WT luciferase reporter gene plasmid but had no effect on that of the XIST-MT plasmid in bladder cancer cells, suggesting that XIST directly targets miR-133a in bladder cancer cells.

### Downregulation of miR-133a in bladder cancer

The expression levels of miR-133a in bladder cancer were then assessed. As presented in [Fig. 4A](#f4-etm-0-0-7960){ref-type="fig"}, miR-133a was significantly downregulated in bladder cancer cells compared with that in SV-HUC-1 cells. Furthermore, the expression levels of miR-133a were significantly downregulated in bladder cancer tissues compared with those in adjacent normal tissues ([Fig. 4B](#f4-etm-0-0-7960){ref-type="fig"}). Further investigation revealed an inverse correlation between miR-133a and XIST expression in bladder cancer tissues ([Fig. 4C](#f4-etm-0-0-7960){ref-type="fig"}), suggesting that the reduced expression of miR-133a may be due to the increased expression of XIST in bladder cancer.

### miR-133a acts as a downstream effector in XIST-mediated bladder cancer cell proliferation and migration

Next, it was assessed whether miR-133a acts as a downstream effector in XIST-mediated bladder cancer cell proliferation and migration. 253J and RT112 cells were co-transfected with NC siRNA and NC inhibitor (siNC+anti-NC), NC siRNA and miR-133a inhibitor (si-NC+anti-miR-133a), XIST siRNA and NC inhibitor (siXIST+anti-NC), or XIST siRNA and miR-133a inhibitor (siXIST+anti-miR-133a). After transfection, the miR-133a levels were significantly reduced in the si-NC+anti-miR-133a group, but significantly increased in the siXIST+anti-NC group, when compared with those in the siNC+anti-NC group ([Fig. 5A and B](#f5-etm-0-0-7960){ref-type="fig"}). However, no significant difference in miR-133a expression was observed between the siNC+anti-NC and siXIST+anti-miR-133a groups. CCK-8 and wound healing assays were then performed to assess the effects of the above treatments on cell proliferation and migration. As indicated in [Fig. 5C-F](#f5-etm-0-0-7960){ref-type="fig"}, the proliferation and migration of bladder cancer cells were significantly increased in the siNC+anti-miR-133a group, but significantly decreased in the siXIST+anti-NC group, when compared with those in the siNC+anti-NC group. In addition, no significant difference was identified between the siNC+anti-NC and siXIST+anti-miR-133a groups ([Fig. 5C-F](#f5-etm-0-0-7960){ref-type="fig"}). These results indicate that inhibition of miR-133a impairs the suppressive effects of XIST downregulation on the proliferation and migration of bladder cancer cells. Therefore, miR-133a acts as a downstream effector in XIST-mediated bladder cancer cell proliferation and migration.

Discussion
==========

It has been demonstrated that lncRNAs affect the expression of a large number of genes and miRNAs at the transcriptional and post-transcriptional levels, through which they regulate various cellular biological processes, including cell proliferation, cell cycle progression, apoptosis, migration and tumourigenesis ([@b10-etm-0-0-7960],[@b11-etm-0-0-7960],[@b21-etm-0-0-7960],[@b26-etm-0-0-7960],[@b27-etm-0-0-7960]). However, the regulatory mechanisms of the lncRNA XIST during bladder cancer progression have remained to be fully elucidated. In the present study, it was indicated that XIST was significantly upregulated in bladder cancer tissues vs. adjacent normal tissues. Furthermore, its expression was also reduced in several common bladder cancer cell lines. High expression of XIST was significantly associated with tumour progression and poor prognosis of patients with bladder cancer. The *in vitro* experiments suggested that knockdown of XIST significantly reduced the proliferation and migration of bladder cancer cells. Furthermore, a luciferase assay confirmed that XIST directly binds with miR-133a at the predicted binding site. It was also determined that miR-133a was significantly downregulated in bladder cancer, and its expression levels were inversely correlated with XIST expression levels in bladder cancer tissues. In addition, loss- and gain-of-function experiments suggested that miR-133a acts as a downstream effector in XIST-mediated bladder cancer cell proliferation and migration.

In recent years, the lncRNA XIST has been reported to be frequently upregulated in certain common types of cancer, and its upregulation is associated with tumour progression and poor prognosis of cancer patients ([@b28-etm-0-0-7960]--[@b30-etm-0-0-7960]). For instance, Yang *et al* ([@b31-etm-0-0-7960]) indicated that the expression of XIST was significantly increased in osteosarcoma tissues and cell lines, and negatively correlated with clinical prognosis. Sun *et al* ([@b32-etm-0-0-7960]) reported that XIST was markedly upregulated in pancreatic cancer, and its overexpression significantly promoted cancer cell proliferation, migration and invasion. In the present study, increased expression of XIST in bladder cancer tissues and cell lines was detected and high expression of XIST was associated with positive metastasis, advanced TNM stage and shorter survival time of bladder cancer patients. Similarly, Xiong *et al* ([@b33-etm-0-0-7960]) also reported that XIST was upregulated in bladder cancer tissues and that higher XIST expression was associated with advanced TNM stage of bladder cancer. In addition, Hu *et al* ([@b22-etm-0-0-7960]) reported that XIST was significantly upregulated in bladder cancer tissues and cell lines, and correlated with poor prognosis of bladder cancer patients. Taken together, the results of previous and the present study suggest that the lncRNA XIST has a key role during bladder cancer progression and may thus serve as a potential therapeutic target.

To further study the function of XIST in tumour growth and metastasis, bladder cancer cells were transfected with XIST siRNA to knock down its expression, and CCK-8 and wound healing assays suggested that the downregulation of XIST caused a significant reduction in bladder cancer cell proliferation and migration. These results suggest that the lncRNA XIST may have a promoting role during bladder cancer growth and metastasis. Consistent with these results, Xiong *et al* ([@b33-etm-0-0-7960]) also reported that XIST knockdown inhibited the proliferation, invasion and migration of bladder cancer cells. In addition, Hu *et al* ([@b22-etm-0-0-7960]) indicated that silencing of XIST expression significantly reduced bladder cancer cell growth and metastasis *in vitro* and tumour growth *in vivo*. However, the molecular mechanisms of the effect of XIST on bladder cancer progression have remained to be fully elucidated.

The present study focused on downstream miRNAs of XIST, as numerous miRNAs have been reported to act as tumour suppressors and oncogenes in bladder cancer ([@b5-etm-0-0-7960],[@b34-etm-0-0-7960]). Bioinformatics analysis predicted that XIST and miR-133a contain mutual binding sites. In fact, several previous studies have reported that miR-133a functions as a tumour suppressor in bladder cancer. For instance, miR-133a was demonstrated to induce bladder cancer cell apoptosis through directly targeting glutathione S-transferase pi 1 ([@b35-etm-0-0-7960]). Zhou *et al* ([@b36-etm-0-0-7960]) reported that miR-133 inhibited the proliferation, migration and invasion of bladder cancer cells by targeting EGFR and its downstream effector proteins. In the present study, it was demonstrated that reduced expression of miR-133a was inversely correlated with increased expression of XIST in bladder cancer tissues and that knockdown of XIST caused an upregulation of miR-133a in bladder cancer cells, suggesting that the increased expression of XIST may contribute to the decreased expression of miR-133a in bladder cancer. Furthermore, it was observed that silencing of miR-133a impaired the inhibitory effects of XIST knockdown on the proliferation and migration of bladder cancer cells, indicating that miR-133a is indeed involved in XIST-mediated bladder cancer. In addition to miR-133a, several other miRNAs, including miR-124 ([@b33-etm-0-0-7960]), miR-139 ([@b22-etm-0-0-7960]) and miR-200 ([@b21-etm-0-0-7960]), have also been identified as target miRNAs of XIST in bladder cancer cells. Xiong *et al* ([@b33-etm-0-0-7960]) reported that XIST directly interacts with miR-124 and thus promotes the expression of androgen receptor in bladder cancer cells. Hu *et al* ([@b22-etm-0-0-7960]) indicated that XIST promoted bladder cancer cell growth and metastasis through interacting with miR-139-5p and thus affected the activity of the Wnt/β-catenin signalling pathway. The present study enhances the current understanding of the function of the XIST/miRNA axis in bladder cancer cells. Future studies should focus on identifying the downstream protein targets of miR-133a in bladder cancer.

In conclusion, the present study demonstrated for the first time that XIST promotes bladder cancer cell proliferation and migration via modulation of miR-133a and thus suggests that XIST may be used as a potential therapeutic target for bladder cancer.
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![Upregulation of XIST in bladder cancer. (A) qPCR was used to examine XIST expression in the normal urinary tract epithelial cell line SV-HUC-1 and 4 bladder cancer cell lines. \*\*P\<0.01 vs. SV-HUC-1. (B) qPCR was used to examine the XIST expression in 52 paired bladder cancer tissues and adjacent normal tissues. \*\*P\<0.01 vs. Adjacent. (C) High XIST expression was significantly associated with a shorter survival time of bladder cancer patients. XIST, X inactive specific transcript; qPCR, quantitative polymerase chain reaction.](etm-18-05-3475-g00){#f1-etm-0-0-7960}

![Inhibition of XIST suppresses bladder cancer cell proliferation or migration. 253J and RT112 cells were transfected with NC siRNA, XIST siRNA1 or XIST siRNA2. (A) qPCR was used to examine the expression of XIST. (B and C) A Cell Counting Kit-8 assay and (D and E) a wound healing assay (magnification, ×40) were used to assess the effects of the treatments on cell proliferation and migration, respectively. \*\*P\<0.01 vs. siNC. XIST, X inactive specific transcript; siRNA, small interfering RNA; siNC, negative control siRNA; siXIST, siRNA targeting XIST; OD, optical density.](etm-18-05-3475-g01){#f2-etm-0-0-7960}

![XIST directly targets miR-133a in bladder cancer cells. (A) Bioinformatics analysis suggested that miR-133a has putative XIST binding sites, and luciferase reporter plasmids containing the WT and MT miR-133a binding sites in XIST were generated. (B) Knockdown of XIST significantly promoted miR-133a expression in 253J and RT112 cells. \*\*P\<0.01 vs. siNC. (C and D) Luciferase reporter gene assay suggested that transfection with miR-133a mimics decreased the luciferase activity of WT XIST reporter plasmid, while not affecting the luciferase activity of MT XIST reporter plasmid in 253J and RT112 cells. \*\*P\<0.01 vs. miR-NC. XIST, X inactive specific transcript; miR, microRNA; miR-NC, miR mimics negative control; WT, wild type; MT, mutant type; siRNA, small interfering RNA; siNC, negative control siRNA; siXIST, siRNA targeting XIST.](etm-18-05-3475-g02){#f3-etm-0-0-7960}

![miR-133a is downregulated in bladder cancer tissues and cell lines. (A) RT-qPCR was used to examine the miR-133a expression in a normal urinary tract epithelial cell line SV-HUC-1 and 4 bladder cancer cell lines. \*\*P\<0.01 vs. SV-HUC-1. (B) RT-qPCR was used to examine the miR-133a expression in 52 paired bladder cancer tissues and adjacent normal tissues. \*\*P\<0.01 vs. Adjacent. (C) Inverse correlation between miR-133a and XIST expression in bladder cancer tissues. XIST, X inactive specific transcript; miR, microRNA; RT-qPCR, reverse-transcription quantitative PCR.](etm-18-05-3475-g03){#f4-etm-0-0-7960}

![miR-133a acts as a downstream effector in XIST-mediated bladder cancer cell proliferation and migration. 253J and RT112 cells were co-transfected with NC siRNA and NC inhibitor, NC siRNA and miR-133a inhibitor, XIST siRNA and NC inhibitor or XIST siRNA and miR-133a inhibitor, respectively. (A and B) The expression of XIST was examined using reverse-transcription quantitative PCR. (C and D) A Cell Counting Kit-8 assay and (E and F) a wound healing assay (magnification, ×40) were performed to assess cell proliferation and migration, respectively. \*\*P\<0.01 vs. si-NC+anti-NC. XIST, X inactive specific transcript; miR, microRNA; anti-miR-133a, miR-133a inhibitor; anti-NC, miR inhibitor control, siRNA, small interfering RNA; siNC, negative control siRNA; siXIST, siRNA targeting XIST; OD, optical density.](etm-18-05-3475-g04){#f5-etm-0-0-7960}

###### 

Association between XIST expression and clinicopathological characteristics in bladder cancer.

                                   XIST expression        
  --------------------------- ---- ----------------- ---- -------
  Age (years)                                             0.546
    \<55                      18   8                 10   
    ≥55                       34   11                23   
  Sex                                                     0.558
    Male                      32   13                19   
    Female                    20   6                 14   
  Degree of differentiation                               0.095
    Well/moderate             40   12                28   
    Poor                      12   7                 5    
  Lymph node metastasis                                   0.001
    No                        33   6                 27   
    Yes                       19   13                6    
  Distant metastasis                                      0.001
    No                        46   13                33   
    Yes                       6    6                 0    
  TNM stage                                               0.001
    I/II                      28   4                 24   
    III/IV                    24   15                9    

TNM, tumour-nodes-metastasis; XIST, X inactive specific transcript.
